I am an endocrinologist with particular interest in bone metabolism in people with cancer. I see both patients with benign metabolic bone diseases, such as osteoporosis and hyperparathyroidism, and bone disorders due to advanced cancer, such as hypercalcemia and metastatic bone disease. Much of my research has focused on rare complications of a subset of bone protective drugs known as antiresorptives. I have twice served on the National Comprehensive Cancer Care Network’s Bone Health in Cancer Care task force.
In addition to bone metabolism, I treat a large number of patients with diabetes. I intend to conduct future research on the long-term effects of adjuvant aromatase inhibitors on fracture risk in women with breast cancer and on thyroid cancer and metastatic bone disease.
- Clinical Expertise: Diabetes Mellitus; Disorders of Bone and Mineral Metabolism (Osteoporosis, Hyperparathyroidism, Hypercalcemia, Hypocalcemia); Bone loss as a result of various cancer treatments (such as aromatase inhibitors)
- Languages Spoken: English
- Education: MD, University of Medicine and Dentistry of New Jersey (UMDNJ), New Jersey Medical School
- Residencies: Temple University Hospital
- Fellowships: UMDNJ, Robert Wood Johnson University Hospital
- Board Certifications: Endocrinology
As home to one of the world’s top cancer research centers, Memorial Sloan Kettering is typically involved in more than 900 clinical trials at a given time. Currently, clinical trials focused on the conditions I treat are enrolling new patients. If you’re interested in joining a clinical trial, click to learn about the trial’s purpose, eligibility criteria, and how to get more information.Learn more
Most major health insurers offer plans that include MSK as one of their in-network providers. If MSK is in-network, it means all our doctors are too. Medicaid and New York State Medicare also provide benefits for care at MSK.Learn more